Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | IKBKB | O14920 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20400026 | 1.00 | HRH1 (0.43) | HRH1EPHX2IKBKBMAP4K4CYP2C9 | |
| SCHEMBL77615 | 0.91 | PARP10 (0.48) | HRH1EPHX2IKBKBPARP10CHRNB2 | |
| SCHEMBL28179921 | 0.91 | CYP19A1 (0.44) | HRH1EPHX2IKBKBPARP10CHRNB2 | |
| SCHEMBL15574983 | 0.89 | MAP4K4 (0.39) | HRH1EPHX2IKBKBMAP4K4CYP2C9 | |
| SCHEMBL14634351 | 0.89 | EPHX2 (0.41) | HRH1EPHX2IKBKBMAP4K4CYP2C9 | |
| SCHEMBL15574985 | 0.89 | MAP4K4 (0.39) | HRH1EPHX2IKBKBMAP4K4CYP2C9 | |
| SCHEMBL2551059 | 0.89 | EPHX2 (0.41) | HRH1EPHX2IKBKBMAP4K4CYP2C9 | |
| SCHEMBL29324903 | 0.89 | EPHX2 (0.41) | HRH1EPHX2IKBKBMAP4K4CYP2C9 | |
| SCHEMBL14654942 | 0.89 | CYP19A1 (0.49) | HRH1EPHX2IKBKBGRIN1GRIN2B | |
| SCHEMBL13165443 | 0.89 | CYP19A1 (0.46) | HRH1EPHX2PARP10GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12589156-B2 | Benzimidazole and benzimidazolone based protac compounds for the targeted degradation of leucine rich repeat kinase 2 (LRRK2) | ARVINAS OPERATIONS, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| EP-4665456-A1 | BENZIMIDAZOLE AND BENZIMIDAZOLONE BASED PROTAC COMPOUNDS FOR THE TARGETED DEGRADATION OF LEUCINE RICH REPEAT KINASE 2 (LRRK2) | Arvinas Operations, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250228952-A1 | BENZIMIDAZOLE AND BENZIMIDAZOLONE BASED PROTAC COMPOUNDS FOR THE TARGETED DEGRADATION OF LEUCINE RICH REPEAT KINASE 2 (LRRK2) | ARVINAS OPERATIONS, INC. | 2025-07-17 | — | — | US | disclosed |
| WO-2025072629-A1 | BENZIMIDAZOLE AND BENZIMIDAZOLONE BASED PROTAC COMPOUNDS FOR THE TARGETED DEGRADATION OF LEUCINE RICH REPEAT KINASE 2 (LRRK2) | ARVINAS OPERATIONS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250228952-A1 | BENZIMIDAZOLE AND BENZIMIDAZOLONE BASED PROTAC COMPOUNDS FOR THE TARGETED DEGRADATION OF LEUCINE RICH REPEAT KINASE 2 (LRRK2) | LRRK2, PINK1, PSMC1 | HRH1 1594/4885EPHX2 4661/4885IKBKB 1536/4885 |
| US-12589156-B2 | Benzimidazole and benzimidazolone based protac compounds for the targeted degradation of leucine rich repeat kinase 2 (LRRK2) | LRRK2, SNCA, PARK7 | HRH1 2843/4885EPHX2 4802/4885IKBKB 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.